Last $1.62 USD
Change Today +0.06 / 3.85%
Volume 374.3K
OXGN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Open
$1.58
Previous Close
$1.56
Day High
$1.64
Day Low
$1.55
52 Week High
03/12/14 - $5.40
52 Week Low
12/15/14 - $1.48
Market Cap
33.5M
Average Volume 10 Days
452.8K
EPS TTM
$-1.73
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression. Its principal clinical product candidate is ZYBRESTAT, which is in development as a treatment for solid tumors. The company is also developing OXi4503, a second-generation product candidate for acute myeloid leukemia. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

9 Employees
Last Reported Date: 03/20/14
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $241.3K
Compensation as of Fiscal Year 2013.

oxigene inc (OXGN) Key Developments

OXiGENE, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

OXiGENE, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $3,453,000 against $2,647,000 a year ago. Net loss attributable to common stock was $3,450,000 or $0.17 per basic and diluted share against $4,964,000 or $1.88 per basic and diluted share a year ago. For the nine months, the company reported loss from operations of $10,005,000 against $6,183,000 a year ago. Net loss attributable to common stock was $10,009,000 or $0.64 per basic and diluted share against $10,979,000 or $4.84 per basic and diluted share a year ago.

OXiGENE, Inc. Announces Positive Results from the Phase 2 GOG 186I Study of Fosbretabulin Combined with Bevacizumab in Recurrent Ovarian, Tubal and Peritoneal Carcinoma

OXiGENE, Inc. announced the first presentation at a scientific conference of the positive results from the Phase 2 GOG 186I study of fosbretabulin combined with bevacizumab in recurrent ovarian, tubal and peritoneal carcinoma. The detailed data were presented by the Gynecologic Oncology Group (GOG), now part of NRG Oncology, in an oral presentation at the 15(th) Biennial Meeting of the International Gynecologic Cancer Society (IGCS) meeting held in Melbourne, Australia. The study achieved its primary endpoint and demonstrated a statistically significant increase in progression-free survival (PFS) for the combination as compared to bevacizumab alone (p=0.049; HR=0.685). The study enrolled 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States. Median PFS was 7.3 months for bevacizumab plus fosbretabulin (n=54) compared to 4.8 months with bevacizumab (n= 53). In a post-hoc subgroup analysis, data showed that patients who were platinum-resistant also had a statistically significant improvement in PFS with the combination. Among these 27 patients, median PFS was 6.7 months for those on bevacizumab and fosbretabulin compared to 3.4 months for those receiving bevacizumab alone (p=0.01; HR=0.57). Although the subgroup included a relatively small number of patients, these findings suggest that adding fosbretabulin to bevacizumab has a potentially greater effect in this difficult-to-treat patient group than for platinum-sensitive patients. Patients with measurable disease who received the combination of fosbretabulin and bevacizumab may achieve a higher objective response rate (ORR), a secondary endpoint in the study measured according to RECIST criteria. Although not a statistically significant result, patients receiving the combination had an ORR of 35.7% (n=42) compared to 28.2% for patients on bevacizumab alone (n=39). In the small subgroup of platinum-resistant patients, the addition of fosbretabulin to bevacizumab treatment increased ORR to 40% (n=10) compared to 12.5% (n=8) for bevacizumab. Additional secondary endpoints in the study included safety and overall survival. All treatment- related adverse events in the study were manageable, with one Grade 4 event occurring in each treatment arm. Consistent with prior clinical experience with fosbretabulin, patients in the combination arm experienced an increased incidence of Grade 3 hypertension compared to the control arm (10 cases for bevacizumab as compared to 17 for the combination). All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol. Patients continue to be followed for overall survival. A preliminary analysis of 33 events did not demonstrate a difference in overall survival between the study arms. Further analysis of this secondary endpoint will be conducted as the data matures. The Phase 2 study was conducted by the legacy GOG, now part of NRG Oncology, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). In protocol 186I, 107 patients with recurrent ovarian cancer were randomized 1:1 into one of two treatment arms: one arm received bevacizumab, and the second arm received fosbretabulin plus bevacizumab. Both therapies were administered intravenously every three weeks and patients were treated until disease progression or until adverse effects prohibited further therapy. For this study, fosbretabulin was provided to CTEP under a Cooperative Research and Development Agreement (CRADA) with OXiGENE, and bevacizumab was provided as an investigational agent under a CRADA with Genentech. Bevacizumab is not approved to treat women with ovarian cancer in the United States; however, it is approved in other countries for treatment of ovarian cancer.

OXiGENE, Inc. to Report Q3, 2014 Results on Nov 12, 2014

OXiGENE, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $1.62 USD +0.06

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies
 

Industry Analysis

OXGN

Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXIGENE INC, please visit www.oxigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.